Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
The present invention provides methods for treating lysosomal storage disorders such as Gaucher's disease, by using compounds of Formula III as described herein.
1 . A method for treating a Gaucher's disease, which comprises administering to the patient in need thereof an effective amount of a compound of Formula III:
wherein:
R 1 is C(R 2 )(R 3 )(R 4 );
R 2 is selected from the group consisting of hydrogen, —OH or halogen;
R 3 is selected from the group consisting of hydrogen, —OH, halogen or —CH 3 ;
R 4 is selected from the group consisting of hydrogen, halogen, —CH 3 , phenyl, fluorophenyl, methylphenyl or cyclohexylmethyl;
R 3 and R 4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;
R 6 is selected from the group consisting of —OH or halogen;
R 8 is selected from the group consisting of —OH or halogen; and
R 10 is selected from the group consisting of —OH or halogen, provided that that at least one of R 2 , R 3 , R 4 , R 6 , R 8 or R 10 comprises a halogen.
2 . A method for treating Gaucher's disease, which comprises administering to the patient in need thereof an effective amount of a compound selected from the group consisting of the following:
or a pharmaceutically acceptable salt, or solvate, or prodrug thereof.
3 . The method of claim 2 , further comprising administering an effective amount of at least one other therapeutic agent selected from the group consisting of imiglucerase or 1,5-(butylimino)-1,5-dideoxy-D-glucitol.
4 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
5 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
6 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
7 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
8 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
9 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
10 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
11 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
12 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
13 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
14 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
15 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.
16 . The method of claim 2 , wherein the compound comprises
or a pharmaceutically acceptable salt or solvate thereof.